Humacyte, Inc. (HUMA)
NASDAQ
Healthcare
Biotechnology
$1.08
▲ +2.37%
Market Cap
$181.4M
Sector
Healthcare
Industry
Biotechnology
Beta
2.46
52-Wk Range
0.547-2.84
CEO
Laura E. Niklason
Country
US
Currency
USD
Humacyte, Inc. focuses on developing and manufacturing readily available, implantable human tissues engineered in a laboratory setting. These bioengineered tissues are designed to treat a wide array of diseases and conditions across various anatomical locations and therapeutic fields. The company employs its distinct scientific and proprietary technology platform to produce human acellular vessels (HAVs). These investigational HAVs are specifically crafted for universal compatibility, enabling easy implantation into any patient without inducing an immune rejection or an adverse foreign body re…
Open full interactive analysis & DCF →